BIOMAT Database Logo BIOMAT Database Logo

Diphenylhydantoin-induced gingival hyperplasia: its response to changes in drug dosage. 1975

T M Little, and S S Girgis, and R E Masotti

Changes in gingival hyperplasia were studied in 48 patients treated for epilepsy with diphenylhydantoin (DPH) over a two-year period. During this time changes in the dose of DPH were made in some patients in order to increase control of seizures or decrease side-effects: in 27 patients the dose was increased, in nine it was decreased and in 12 the dose remained unchanged. It was found that the severity of gingival hyperplasia varied directly with both the dose and serum level of the drug.

UI MeSH Term Description Entries
D008297 Male Males
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D005260 Female Females
D005885 Gingival Hyperplasia Non-inflammatory enlargement of the gingivae produced by factors other than local irritation. It is characteristically due to an increase in the number of cells. (From Jablonski's Dictionary of Dentistry, 1992, p400) Gingival Hyperplasias,Hyperplasia, Gingival,Hyperplasias, Gingival
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

T M Little, and S S Girgis, and R E Masotti
Diphenylhydantoin (dilantin) gingival hyperplasia: drug-induced abnormality of connective tissue.
August 1976, Proceedings of the National Academy of Sciences of the United States of America,
T M Little, and S S Girgis, and R E Masotti
Antihistamines and diphenylhydantoin-induced gingival hyperplasia.
September 1958, The New England journal of medicine,
T M Little, and S S Girgis, and R E Masotti
Diphenylhydantoin gingival hyperplasia.
March 1969, American journal of diseases of children (1960),
T M Little, and S S Girgis, and R E Masotti
Folate treatment of diphenylhydantoin-induced gingival hyperplasia.
June 1989, Scandinavian journal of dental research,
T M Little, and S S Girgis, and R E Masotti
Gingival hyperplasia induced by diphenylhydantoin in a gorilla.
November 1979, Journal of the American Veterinary Medical Association,
T M Little, and S S Girgis, and R E Masotti
[Gingival hyperplasia and diphenylhydantoin].
January 1984, Parodontologia e stomatologia (nuova) : organo ufficiale dell'ARPA italiana, della Societa italiana Jonoforesi stomatologica e della Accademia ligustica di stomatologia,
T M Little, and S S Girgis, and R E Masotti
Gingival hyperplasia and diphenylhydantoin.
July 1972, Journal of periodontology,
T M Little, and S S Girgis, and R E Masotti
[Drug induced gingival hyperplasia and its therapy].
August 1976, Deutsche zahnarztliche Zeitschrift,
T M Little, and S S Girgis, and R E Masotti
Diphenylhydantoin induced gingival hyperplasia in ferrets: a precautionary note.
August 1979, Journal of dental research,
T M Little, and S S Girgis, and R E Masotti
[Histopathological study on diphenylhydantoin gingival hyperplasia in rats, especially the role of gingival inflammation in diphenylhydantoin gingival hyperplasia].
September 1982, Nihon Shishubyo Gakkai kaishi,
Copied contents to your clipboard!